Disrupting Circadian Rhythm via the PER1–HK2 Axis Reverses Trastuzumab Resistance in Gastric Cancer

Trastuzumab is the only approved targeted drug for first-line treatment of HER2-positive advanced gastric cancer, but the high rate of primary resistance and rapid emergence of secondary resistance limit its clinical benefits. We found that trastuzumab-resistant (TR) gastric cancer cells exhibited h...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jiao, Huang, Qiong, Hu, Xingbin, Zhang, Shuyi, Jiang, Yu, Yao, Guangyu, Hu, Kongzhen, Xu, Xin, Liang, Bishan, Wu, Qijing, Ma, Zhenfeng, Wang, Yawen, Wang, Chunlin, Wu, Zhenzhen, Rong, Xiaoxiang, Liao, Wangjun, Shi, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Metabolism and Chemical Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662874/
https://www.ncbi.nlm.nih.gov/pubmed/35255118
http://dx.doi.org/10.1158/0008-5472.CAN-21-1820

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662874/
https://www.ncbi.nlm.nih.gov/pubmed/35255118
http://dx.doi.org/10.1158/0008-5472.CAN-21-1820

Ejemplares similares